SeraNovo and AstraZeneca Collaborate on Future Research Projects
This deal would help the companies merge to work on future projects and conduct research together.
SeraNovo, a formulation technology provider based in Leiden, The Netherlands, announced a multi-compound deal with AstraZeneca on May 17, 2023. This deal would help the companies merge to work on future projects and conduct research together.
“SeraNovo has grown substantially in recent years in terms of our technical capabilities and worldwide customer base. It is great to be able to share news of one of our most important collaborations with such a historic company. Our technology will again be used to drive important therapies to patients. We look forward to a long and prosperous relationship with AstraZeneca,” said Niall Hodgins, chief executive officer of SeraNovo, in a press release.
Source: SeraNovo
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
